Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020748 · ClinicalTrials.gov registry record · Phase 1
Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer
A Phase 1 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00020748: Completed Phase 1 study, sponsored by Georgetown University.
NCT00020748 is a Phase 1 study that has completed, run by Georgetown University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020748, a Phase 1 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of epirubicin plus irinotecan in treating patients who have advanced cancer.
Interventions
- DRUG epirubicin hydrochloride
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-08 |
| Est. Completion | 2004-10 |
| Phase | Phase 1 |
What the finished NCT00020748 record still lists
NCT00020748 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which epirubicin hydrochloride is the first listed.
NCT00020748 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00020748 about?
NCT00020748 is a clinical study titled "Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of epirubicin plus irinotecan in treating patients who have advanced canc...
What is the current status of trial NCT00020748?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-08. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00020748?
The interventions under investigation include: epirubicin hydrochloride (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00020748?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia